AI business Recursion Pharmaceuticals has narrowed its drug development pipeline, ending or pausing five programmes as it seeks to reduce costs and reprioritise resources following a merger with ...

It continues to draw limited revenue, while its costs are growing notably. For the quarter, Recursion -- which although a clinical-stage company earns some coin from collaboration agreements with ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes ...

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.39 per share a year ago.

Recursion said it will end development for four of its 11 pipeline programs—one of which the company will consider outlicensing to a partner instead—and pause a fifth program, in a pruning ...

Recursion Pharmaceuticals (NASDAQ: RXRX) didn't have a fine start to the working week on Monday, at least as far as its stock was concerned. Investors traded out of it following the clinical-stage ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) are tumbling on Tuesday. The stock lost 10.3% as of 2:50 p.m. ET and was down by as much as 11.8% earlier in the day. The move comes as the S&P ...

"Recursion's decade-long investment in AI is driving a decisive, data-led portfolio strategy," said Chris Gibson, Co-Founder and CEO of Recursion. "We are prioritizing high-potential programs to ...